AccuGenomics is pleased to announce that it has received notification of a grant award from NIIMBL (the National Institute for Innovation in Manufacturing Biopharmaceuticals). This award is from a grant submission entitled “Development of SARS-CoV-2 NGS Internal Standards to Ensure Sufficient Complexity Capture for Variant Detection and Diagnosis”, and is valued at $437,282. There is an ongoing need for controls to confirm analytic performance of SARS-CoV-2 sequencing as part of the continued global effort to detect and track new COVID variants.
NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally-sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members.
AccuGenomics manufactures innovative multiplexed spike-in QC standards (SNAQ™-SEQ) that enable a host of highly sensitive next generation sequencing applications. SNAQ™-SEQ internal standards improve the accuracy and performance of NGS-based assays. Our corporate headquarters includes over 5000 sf of development and manufacturing suites and are located in Wilmington, NC. AccuGenomics is pleased to continue our partnership to NIIMBL and its wide network of member organizations.
Interested parties are invited to contact us for additional information or partnership discussions.